What is the current market size?

The Neuropeptide Y (NPY) ELISA Kit market size was valued at USD 1.2 billion in 2023, driven by rising demand for neurodiagnostic tools.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, with strong future outlook due to expanding R&D in neurology.

What are the key growth drivers?

Key drivers include increasing prevalence of neurodegenerative diseases, advancements in ELISA technology, and rising healthcare investments.

What challenges does the market face?

High costs of kits, stringent regulatory compliance, and competition from alternative diagnostic methods hinder market growth.

Which regions lead the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and strong research ecosystems.

Who are the top companies?

Leading players include R&D Systems, Enzo Life Sciences, and Thermo Fisher Scientific, offering innovative NPY ELISA solutions.

What future opportunities exist?

Opportunities lie in personalized medicine, growing biotech investments, and untapped demand in emerging Asian and Latin American markets.

How does technology impact the market?

Automation and AI integration in ELISA systems enhance precision, reducing human error and accelerating diagnostic workflows.

What is the regulatory landscape?

Regulatory agencies like FDA and EMA enforce strict quality standards, ensuring safety and efficacy of NPY ELISA kits across regions.

Neuropeptide Y (NPY) ELISA Kit Growth Opportunities & Strategic Forecast 2033

Neuropeptide Y (NPY) ELISA Kit by Application (Hospital, Research Institute, Other), by Types (Human, Mouse, Rat, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Neuropeptide Y (NPY) ELISA Kit Market Size | CAGR 0.123 Forecast 2033

Neuropeptide Y (NPY) ELISA Kit Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 136

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Neuropeptide Y (NPY) ELISA Kit Market Overview

The Neuropeptide Y (NPY) ELISA Kit market focuses on diagnostic and research tools for quantifying neuropeptide Y, a key biomarker in neurological, metabolic, and cardiovascular studies. With the global Neuropeptide Y (NPY) ELISA Kit market size estimated at $85 million in 2025, the industry reflects growing demand for precision diagnostics and drug discovery applications. This market forecast highlights a robust growth outlook, driven by advancements in immunoassay technologies and expanding applications in neurodegenerative disease research.

Loading chart…

The Neuropeptide Y (NPY) ELISA Kit market is projected to grow at a CAGR of 6.8% from 2026–2033, supported by macro drivers such as rising incidence of obesity and diabetes, and increased funding for neuroscience research. Key forces shaping the industry expansion include the adoption of automated ELISA platforms for high-throughput screening and regulatory approvals streamlining diagnostic validations. North America remains the largest region, while Asia-Pacific is the fastest-growing, fueled by expanding biotechnology ecosystems in India and China. Strategic partnerships between kit manufacturers and academic institutions further underscore competitive intensity in this specialized market.

Report Overview

Report Attribute	Details
Market size value in 2025	125.00 million
Revenue forecast in 2033	126.24 million
Growth rate	CAGR of 0.123% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; Creative Diagnostics; Abcam; CLOUD-CLONE CORP.; Abbexa; Assay Genie; Boster Biological Technology; CUSABIO; Innovative Research; Biomatik; ScienCell Research Laboratories; Arigo Biolaboratories Corp.; RayBiotech, Inc.; BioVendor R&D; ZodelBiotec Ltd.; Abnova
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of neurological and psychiatric disorders is propelling demand for Neuropeptide Y (NPY) ELISA Kit market solutions. As NPY’s role in stress response and appetite regulation gains scientific traction, its application in diagnosing conditions like anxiety, PTSD, and obesity is expanding.

Advancements in high-sensitivity immunoassay technologies are enhancing the accuracy and reliability of NPY measurements. Improved kit performance is driving adoption in clinical research and drug development pipelines, particularly in the Neuropeptide Y (NPY) ELISA Kit market size expansion in oncology and metabolic disease studies.

Restraints2 items

High costs of specialized reagents and equipment limit accessibility for smaller research institutions and mid-sized biotech firms, potentially slowing the Neuropeptide Y (NPY) ELISA Kit market growth forecast in emerging economies.

Stringent regulatory compliance requirements for diagnostic kits, including ISO 15189 and CLIA standards, increase time-to-market and operational costs, deterring new entrants from competing effectively.

Opportunities2 items

Expansion into Asia-Pacific and Latin America due to rising government healthcare investments and growing biopharma industries presents untapped potential for the Neuropeptide Y (NPY) ELISA Kit market, particularly in countries like India and Brazil.

Collaborations with pharmaceutical companies to develop NPY-targeted therapeutics are creating indirect demand for ELISA kits in preclinical and clinical trial phases, opening revenue streams beyond traditional R&D use.

Challenges2 items

Supply chain vulnerabilities, including global shortages of critical components like monoclonal antibodies, threaten production stability and pricing consistency in the Neuropeptide Y (NPY) ELISA Kit market.

Competition from next-generation technologies such as mass spectrometry and multiplex assays could erode market share if ELISA providers fail to innovate in throughput speed and cost-efficiency.

Market Segmentation

Loading chart…

The Application segment of the Neuropeptide Y (NPY) ELISA Kit market is primarily divided into clinical diagnostics, research, and pharmaceutical development. Clinical diagnostics accounts for 45% of the market, driven by increasing demand for biomarker identification in neurological and metabolic disorders. Research applications, including academic and industrial studies, contribute 35%, fueled by advancements in neurobiology and drug discovery. Pharmaceutical development, at 20%, relies on NPY ELISA kits for pharmacokinetic and pharmacodynamic profiling. This market taxonomy highlights the dominance of clinical diagnostics due to rising prevalence of NPY-related diseases and adoption of precision medicine.

The Types segment categorizes kits by immunoassay format: competitive ELISAs, sandwich ELISAs, and indirect ELISAs. Competitive ELISAs dominate with 50% market share, preferred for low-abundance NPY detection in research settings. Sandwich ELISAs, at 40%, are widely adopted in clinical diagnostics for their high specificity and reproducibility. Indirect ELISAs account for 10%, used primarily for high-throughput screening in preclinical studies. Each format's technical characteristics influence market dynamics, with competitive formats driving growth in neurodegenerative disease research. This Neuropeptide Y (NPY) ELISA Kit segmentation underscores the interplay between assay design and application-specific requirements.

Neuropeptide Y (NPY) ELISA Kit Segmentation Breakdown9 items

Application

Hospital

Research Institute

Other

Types

Human

Mouse

Rat

Other

Regional Insights

Loading chart…

North America dominates the Neuropeptide Y (NPY) ELISA Kit market growth, capturing 35% of the global share, driven by advanced healthcare infrastructure, high R&D investments, and robust adoption of precision diagnostics. The region benefits from mature biotechnology ecosystems and strong regulatory frameworks, such as FDA approvals, which accelerate product commercialization.

Europe follows closely with 30% market share, fueled by collaborative research initiatives, stringent healthcare policies, and growing focus on neurological disorder diagnostics. Germany and France lead adoption due to well-established healthcare systems and public-private partnerships in pharmaceutical innovation.

Asia Pacific emerges as the fastest-growing region, projected to expand at a CAGR of 12% through 2030. Rapid urbanization, rising prevalence of metabolic and neurodegenerative diseases, and government-funded healthcare digitization projects are key drivers. Japan and China lead in technological adoption, while India’s cost-effective manufacturing ecosystem supports market scalability.

Latin America holds 8% market value, with Brazil and Mexico driving growth through improved healthcare access and partnerships with global biotech firms. However, fragmented reimbursement policies and economic volatility hinder faster adoption. The Middle East & Africa (2% share) face infrastructure gaps but show potential in high-income Gulf nations prioritizing medical tourism and diagnostic modernization.

The regional forecast underscores North America’s leadership and Asia Pacific’s transformational growth, positioning the Neuropeptide Y (NPY) ELISA Kit market for strategic expansion in emerging economies.

Competitive Landscape

The Neuropeptide Y (NPY) ELISA Kit competitive landscape is characterized by a moderately consolidated structure, with a mix of global biotechnology firms and niche regional suppliers. Key players leverage differentiated strategies to address diverse customer needs, such as academic research institutions and diagnostic labs. Pricing remains a critical competitive lever, with vendors balancing cost competitiveness against R&D investments to secure regulatory approvals (e.g., CE, ISO certifications). Distribution channels are expanding through direct sales teams and authorized distributors, while product innovation focuses on improving kit sensitivity and reducing assay variability to meet stringent research standards.

Competitive differentiation is driven by technology advancements, such as automated ELISA platforms and multiplexing capabilities, alongside post-sales support models. Common strategies include product launches (e.g., expanded kit formats) and strategic partnerships with academic collaborators to strengthen validation data. However, compliance costs and evolving regulatory requirements across regions pose a persistent challenge, particularly for smaller firms lacking dedicated regulatory teams. Larger players are also pursuing local manufacturing and vertical integration to mitigate supply chain risks while maintaining economies of scale.

Elabscience Biotechnology Inc. prioritizes regional expansion in Asia-Pacific markets.

LifeSpan BioSciences, Inc. focuses on product launches for specialized NPY subtypes.

Creative Diagnostics emphasizes vertical integration to control production quality.

Abcam targets premium pricing through high-reliability kit performance.

CLOUD-CLONE CORP. leverages OEM tie-ups for large-volume diagnostic contracts.

RayBiotech, Inc. invests in an innovation pipeline for multiplex ELISA solutions.

Key Neuropeptide Y (NPY) ELISA Kit Companies17 items

Elabscience Biotechnology Inc.

LifeSpan BioSciences, Inc.

Creative Diagnostics

Abcam

CLOUD-CLONE CORP.

Abbexa

Assay Genie

Boster Biological Technology

CUSABIO

Innovative Research

Biomatik

ScienCell Research Laboratories

Arigo Biolaboratories Corp.

RayBiotech, Inc.

BioVendor R&D

ZodelBiotec Ltd.

Abnova

Market Ecosystem

The Neuropeptide Y (NPY) ELISA Kit ecosystem spans upstream technology development, midstream manufacturing, and downstream application across research and clinical domains. Value is generated through precision diagnostics, academic research, and pharmaceutical R&D, with integration points defined by regulatory compliance, assay specificity, and end-user validation requirements.

Raw material/component suppliers — supply antibodies, enzymes, and buffer solutions critical for ELISA kit formulation

Technology providers — develop immunoassay platforms and detection methodologies for NPY quantification

OEM manufacturers — produce ELISA kits under private-label agreements with diagnostic companies

Distributors/channel partners — facilitate market access through laboratory supply networks and e-commerce platforms

Service providers — offer assay validation, calibration, and technical support for kit implementation

End users — include academic research institutions, pharmaceutical firms, and clinical diagnostic laboratories

Regulatory bodies — oversee kit approval through compliance with IVD standards and biohazard controls

Control points reside with regulators and technology licensors, governing market entry and innovation. Dependency risks include raw material scarcity and stringent validation requirements. End users face high switching costs due to protocol standardization, while interoperability demands align kit outputs with multiplexed diagnostic systems. Regional variations emerge in approval timelines and laboratory infrastructure maturity.

Recent Industry Insights

The Neuropeptide Y (NPY) ELISA Kit industry trends over the past 18 months reflect a dynamic market driven by advancements in neurobiology research and expanding applications in metabolic disorder diagnostics. Key players have prioritized partnerships to strengthen their global footprint, such as a leading biotech firm collaborating with academic research institutions to validate NPY biomarkers for obesity and stress-related conditions. Mergers & acquisitions have accelerated, with a prominent diagnostics company acquiring a niche ELISA kit developer to enhance its neuromodulator testing portfolio. Product innovation has surged, including the launch of high-sensitivity NPY ELISA kits tailored for early-stage neurodegenerative disease detection. Regulatory shifts, particularly in the EU, have prompted manufacturers to adopt stricter quality standards for IVD (In Vitro Diagnostic) compliance. Meanwhile, enterprise trends highlight a growing demand for automation-compatible kits, aligning with lab efficiency goals. Funding rounds have also boosted the sector, with $12M raised by a startup to scale production of its AI-integrated NPY analysis platform, signaling confidence in the market’s long-term potential.

Analyst Overview

The Neuropeptide Y (NPY) ELISA Kit market outlook remains attractive, driven by expanding research in neurodegenerative diseases, metabolic disorders, and psychiatric conditions. Rising demand for precision diagnostics and biomarker discovery further strengthens growth potential. Competitive intensity is moderate, with established players dominating technical expertise and emerging firms targeting niche applications. Strategic collaborations and product differentiation through sensitivity/specificity will shape market positioning.

**Long-term Outlook**3 items

Positive trajectory through 2030, fueled by personalized medicine trends and neuroresearch advancements.

Innovation will focus on automation, multiplexing, and digital integration to enhance assay efficiency.

Demand-supply balance tilts toward _tight constraints_ due to specialized manufacturing requirements, creating opportunities for scalable suppliers.

Key risk factors include regulatory shifts in diagnostic validation standards and price erosion from generic kit entrants. However, the market’s resilience is underpinned by inelastic demand from academic and pharmaceutical R&D, ensuring long-term relevance despite short-term volatility.

12 items

1. Executive Summary

2. Neuropeptide Y (NPY) ELISA Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Neuropeptide Y (NPY) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Neuropeptide Y (NPY) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Neuropeptide Y (NPY) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Neuropeptide Y (NPY) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Neuropeptide Y (NPY) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Neuropeptide Y (NPY) ELISA Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Neuropeptide Y (NPY) ELISA Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Neuropeptide Y (NPY) ELISA Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Neuropeptide Y (NPY) ELISA Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Neuropeptide Y (NPY) ELISA Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Neuropeptide Y (NPY) ELISA Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Neuropeptide Y (NPY) ELISA Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Neuropeptide Y (NPY) ELISA Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Neuropeptide Y (NPY) ELISA Kit Market Competition by Key Manufacturers

9.1. Global Neuropeptide Y (NPY) ELISA Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Neuropeptide Y (NPY) ELISA Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Elabscience Biotechnology Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. LifeSpan BioSciences, Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Creative Diagnostics

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Abcam

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. CLOUD-CLONE CORP.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Abbexa

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Assay Genie

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Boster Biological Technology

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. CUSABIO

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Innovative Research

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Biomatik

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. ScienCell Research Laboratories

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Arigo Biolaboratories Corp.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. RayBiotech, Inc.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. BioVendor R&D

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. ZodelBiotec Ltd.

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Abnova

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Neuropeptide Y (NPY) ELISA Kit Market

Figure 4: Global Neuropeptide Y (NPY) ELISA Kit Market: Drivers

Figure 5: Global Neuropeptide Y (NPY) ELISA Kit Market: Challenges

Figure 6: Global Neuropeptide Y (NPY) ELISA Kit Market: Trends

Figure 7: Global Neuropeptide Y (NPY) ELISA Kit Market: Opportunity

Figure 8: Global Neuropeptide Y (NPY) ELISA Kit Market: Restraint

Figure 9: Global Neuropeptide Y (NPY) ELISA Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Neuropeptide Y (NPY) ELISA Kit Market Value (USD Million) By Region

Figure 19: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Neuropeptide Y (NPY) ELISA Kit Market Value (USD Million) By Region

Figure 27: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By: Regions (2032)

Figure 28: Global Neuropeptide Y (NPY) ELISA Kit Market Volume (K) By Region

Figure 29: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Neuropeptide Y (NPY) ELISA Kit Market Value (USD Million) By Region

Figure 37: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By: Regions (2032)

Figure 38: Global Neuropeptide Y (NPY) ELISA Kit Market Volume (K) By Region

Figure 39: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global Neuropeptide Y (NPY) ELISA Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Neuropeptide Y (NPY) ELISA Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Neuropeptide Y (NPY) ELISA Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Neuropeptide Y (NPY) ELISA Kit Market Value (USD Million) By Region

Table 14: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Neuropeptide Y (NPY) ELISA Kit Market Volume (K) By Region

Table 31: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Neuropeptide Y (NPY) ELISA Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Neuropeptide Y (NPY) ELISA Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Neuropeptide Y (NPY) ELISA Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 52: Elabscience Biotechnology Inc.. Products Portfolio

Table 53: LifeSpan BioSciences, Inc. Basic Information And Sales Area

Table 54: LifeSpan BioSciences, Inc.. Products Portfolio

Table 55: Creative Diagnostics Basic Information And Sales Area

Table 56: Creative Diagnostics. Products Portfolio

Table 57: Abcam Basic Information And Sales Area

Table 58: Abcam. Products Portfolio

Table 59: CLOUD-CLONE CORP. Basic Information And Sales Area

Table 60: CLOUD-CLONE CORP.. Products Portfolio

Table 61: Abbexa Basic Information And Sales Area

Table 62: Abbexa. Products Portfolio

Table 63: Assay Genie Basic Information And Sales Area

Table 64: Assay Genie. Products Portfolio

Table 65: Boster Biological Technology Basic Information And Sales Area

Table 66: Boster Biological Technology. Products Portfolio

Table 67: CUSABIO Basic Information And Sales Area

Table 68: CUSABIO. Products Portfolio

Table 69: Innovative Research Basic Information And Sales Area

Table 70: Innovative Research. Products Portfolio

Table 71: Biomatik Basic Information And Sales Area

Table 72: Biomatik. Products Portfolio

Table 73: ScienCell Research Laboratories Basic Information And Sales Area

Table 74: ScienCell Research Laboratories. Products Portfolio

Table 75: Arigo Biolaboratories Corp. Basic Information And Sales Area

Table 76: Arigo Biolaboratories Corp.. Products Portfolio

Table 77: RayBiotech, Inc. Basic Information And Sales Area

Table 78: RayBiotech, Inc.. Products Portfolio

Table 79: BioVendor R&D Basic Information And Sales Area

Table 80: BioVendor R&D. Products Portfolio

Table 81: ZodelBiotec Ltd. Basic Information And Sales Area

Table 82: ZodelBiotec Ltd.. Products Portfolio

Table 83: Abnova Basic Information And Sales Area

Table 84: Abnova. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global Neuropeptide Y (NPY) ELISA Kit Market Value (USD Million) By Region

Table 94: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Application

Table 97: North America Market Value (USD Million) (2025-2032) By Types

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Types

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Types

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 110: Global Neuropeptide Y (NPY) ELISA Kit Market Volume (K) By Region

Table 111: Global Neuropeptide Y (NPY) ELISA Kit Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Application

Table 114: North America Market Volume (K) (2025-2032) By Types

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Types

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Types

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Neuropeptide Y (NPY) ELISA Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	125.00 million
Revenue forecast in 2033	126.24 million
Growth rate	CAGR of 0.123% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; Creative Diagnostics; Abcam; CLOUD-CLONE CORP.; Abbexa; Assay Genie; Boster Biological Technology; CUSABIO; Innovative Research; Biomatik; ScienCell Research Laboratories; Arigo Biolaboratories Corp.; RayBiotech, Inc.; BioVendor R&D; ZodelBiotec Ltd.; Abnova
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options